04/10/2021at 12:45

Janssen presents positive results from phase II RSV vaccine trial

The promising phase IIb data comes shortly after the announcement of plans for a phase III trial.

Photo: Shannon Stapleton/Reuters/Ritzau Scanpix

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Janssen's vaccine against respiratory syncytial virus, known as RSV, has lived up to the company's expectations in the latest study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Analyst thinks RSV vaccine market could reach over USD 10bn
For subscribers
Bavarian Nordic: RSV efforts could be "key to the promised land"
For subscribers
Janssen begins phase III trial of RSV vaccine for older patients
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Sandoz ends its collaboration with the secret CMO that made the contaminated antibiotic product and cannot rule out other drugs could be infected with multi-resistant bacteria.

For subscribers

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.

For subscribers

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Janssen presents positive results from phase II RSV vaccine trial

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

Analyst thinks RSV vaccine market could reach over USD 10bn

Bavarian Nordic: RSV efforts could be "key to the promised land"

Janssen begins phase III trial of RSV vaccine for older patients

Sign up for our newsletter

Front page now

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Zealand Pharma presents positive early-stage results for weight-loss candidate

Genmab promotes senior VP for strategy to executive management

Ambu wins European approval of two fifth-generation bronchoscopes

Further reading

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Novo Nordisk enters collaboration with AI-driven drug discovery company

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Jobs